Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Aronson

Showing results (341-350 of 634) with videos related to

Pageof 64
Sort By:
BMJ (Clinical Research Ed.)|December 17, 2020
Harms and the Xmas factorRobin E Ferner, Jeffrey K Aronson
BMJ (Clinical Research Ed.)|April 4, 2020
Drugs and the renin-angiotensin system in covid-19Jeffrey K Aronson, Robin E Ferner
BMJ (Clinical Research Ed.)|December 16, 2016
Nominal ISOMERs (Incorrect Spellings Of Medicines Eluding Researchers)-variants in the spellings of drug names in PubMed: a database reviewRobin E Ferner, Jeffrey K Aronson
Current Protocols in Pharmacology|March 18, 2017
Biomarkers-A General ReviewJeffrey K Aronson, Robin E Ferner
Drug Safety|December 17, 2009
EIDOS: a mechanistic classification of adverse drug effectsRobin E Ferner, Jeffrey K Aronson
Drug Safety|May 1, 2024
Competing Benefits and Competing Hazards: The Benefit to Harm Balance in Individual Patients in Rational TherapeuticsRobin E Ferner, Jeffrey K Aronson
British Journal of Clinical Pharmacology|February 25, 2012
From basic to clinical neuropharmacology: targetophilia or pharmacodynamics?A Richard Green, Jeffrey K Aronson
British Journal of Clinical Pharmacology|June 4, 2019
The British Pharmacological Society's WDM Paton Memorial Lecture 2019: How doctors were informed about pharmaceutical products through advertising in the British Medical Journal from 1955/6 to 1985/6Jeffrey K Aronson, A Richard Green
British Journal of Clinical Pharmacology|December 1, 1980
Metabolism of an oral tryptophan load III: effect of a pyridoxine supplementA R Green, J K Aronson
BMJ (Clinical Research Ed.)|January 2, 1993
ABC of monitoring drug therapy. Making the most of plasma drug concentration measurementsD J Reynolds, J K Aronson
Pageof 64

Showing results (341-350 of 634) with videos related to

Sort By:
Pageof 64
BMJ (Clinical Research Ed.)|December 17, 2020
Harms and the Xmas factorRobin E Ferner, Jeffrey K Aronson
BMJ (Clinical Research Ed.)|April 4, 2020
Drugs and the renin-angiotensin system in covid-19Jeffrey K Aronson, Robin E Ferner
BMJ (Clinical Research Ed.)|December 16, 2016
Nominal ISOMERs (Incorrect Spellings Of Medicines Eluding Researchers)-variants in the spellings of drug names in PubMed: a database reviewRobin E Ferner, Jeffrey K Aronson
Current Protocols in Pharmacology|March 18, 2017
Biomarkers-A General ReviewJeffrey K Aronson, Robin E Ferner
Drug Safety|December 17, 2009
EIDOS: a mechanistic classification of adverse drug effectsRobin E Ferner, Jeffrey K Aronson
Drug Safety|May 1, 2024
Competing Benefits and Competing Hazards: The Benefit to Harm Balance in Individual Patients in Rational TherapeuticsRobin E Ferner, Jeffrey K Aronson
British Journal of Clinical Pharmacology|February 25, 2012
From basic to clinical neuropharmacology: targetophilia or pharmacodynamics?A Richard Green, Jeffrey K Aronson
British Journal of Clinical Pharmacology|June 4, 2019
The British Pharmacological Society's WDM Paton Memorial Lecture 2019: How doctors were informed about pharmaceutical products through advertising in the British Medical Journal from 1955/6 to 1985/6Jeffrey K Aronson, A Richard Green
British Journal of Clinical Pharmacology|December 1, 1980
Metabolism of an oral tryptophan load III: effect of a pyridoxine supplementA R Green, J K Aronson
BMJ (Clinical Research Ed.)|January 2, 1993
ABC of monitoring drug therapy. Making the most of plasma drug concentration measurementsD J Reynolds, J K Aronson
Pageof 64